In a report released yesterday, Gena Wang from Barclays reiterated a Sell rating on Puma Biotechnology (PBYI – Research Report), with a price target of $2.00. The company’s shares closed yesterday at $3.52.
Wang covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Vir Biotechnology, and PTC Therapeutics. According to TipRanks, Wang has an average return of 11.8% and a 44.99% success rate on recommended stocks.
Puma Biotechnology has an analyst consensus of Hold, with a price target consensus of $5.00.
See today’s best-performing stocks on TipRanks >>
Based on Puma Biotechnology’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $46.79 million and a net profit of $1.4 million. In comparison, last year the company earned a revenue of $45.74 million and had a GAAP net loss of $3.4 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Puma Biotechnology, Inc. is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
